We are committed to developing the world's first 'off-the-shelf' cell therapy to destroy all solid tumours, irrespective of strain or mutation. We are achieving this by bringing to market a first in class allogeneic innate cell therapy called N-LIfT, which is simple to produce, scale, store and administer. 


Our first Mission is to show remission in high unmet need solid tumours by 2024,

with an initial focus on pancreatic cancer.